Gabather AB
Develops therapeutics for CNS disorders by targeting the GABAA receptor system.
GABA | ST
Overview
Corporate Details
- ISIN(s):
- SE0010869552 (+1 more)
- LEI:
- 549300VLUOMD0TE1O093
- Country:
- Sweden
- Address:
- FORSKARGATAN 20 J, 151 36 Södertälje
- Website:
- https://gabather.com/
- Sector:
- Manufacturing
Description
Gabather AB is a pharmaceutical company developing next-generation therapeutics for neuropsychiatric and other Central Nervous System (CNS) disorders. The company's approach focuses on restoring brain balance by targeting the GABAA receptor system. Its proprietary drug candidates aim to enhance cognitive function. The lead candidate, GT-002, has completed Phase I clinical trials, demonstrating a favorable safety and tolerability profile. Gabather's development program targets major unmet medical needs across four key areas: anti-psychotics, anti-depressants/anxiolytics, analgesics, and cognition-enhancing treatments for conditions such as Schizophrenia and Alzheimer's disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Gabather AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Gabather AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Gabather AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
